<ul>
<li>与其出售，不如在五月购买这些分红股票，然后离开。</li>
</ul>
<ul>
<li>这些分红贵族股票既有上涨潜力，又支付分红。</li>
</ul>
<ul>
<li>这些分红也很可能会继续上升。</li>
</ul>
<ul>
<li>你在退休方面是领先还是落后？SmartAsset 的免费工具可以在几分钟内将你与财务顾问匹配，帮助你今天回答这个问题。每位顾问都经过严格筛选，必须以你的最佳利益为重。不要再浪费时间；点击这里开始吧。(赞助)</li>
</ul>
<p>随着对关税的担忧开始减弱，股市一直处于上涨状态。财报季也表现良好，大多数科技公司迄今为止都超出了预期。因此，尽管长期宏观前景仍不明朗，许多投资者已经开始重新买入。</p>
<p>在某些股票上买入抄底并不是一个坏主意，因为政府已经软化了对关税的立场。中国 reportedly 正在考虑与美国进行关税谈判，随着库存的耗尽，有效的禁运不太可能持续太久。</p>
<p>由于关税，市场大多下跌，因此任何关于关税被撤回的消息都应该会导致股市的复苏。但即便如此，第一季度的负 GDP 报告和贸易政策的快速变化带来的突然冲击可能会导致未来的下滑。“解放日” 关税和与中国的升级始于四月，因此这些关税的真正影响可能还在前方。而第二季度的负 GDP 报告意味着技术性衰退。</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<p>考虑到这一点，在你的投资组合中增加一些分红贵族股票作为防御性资产仍然是个好主意。</p>
<h2>T Rowe Price (TROW)</h2>
<p><strong>Rowe Price</strong> (NASDAQ:TROW) 的交易价格处于历史低位，尽管过去五年并不稳定，但现在已回到难以忽视的价格。该股在 2020 年下半年飙升，随后在接下来的几年中表现平平。自 2022 年下半年以来，它大多在 90 到 130 美元的区间内交易，目前处于该区间的下端。</p>
<p>尽管如此，技术面并不是这里唯一的亮点。它的市盈率仅为 10 倍，估值相对便宜。历史上，这里的中位数大约为 15 倍。尽管净流出，但该公司在第一季度发布了超出预期的财报。该公司报告 2025 年第一季度净流出 86 亿美元，主要来自美国股票，尽管这仅为上一季度 193 亿美元流出的不到一半。但即便如此，第一季度每股收益为 2.23 美元，超过了 2.12 美元的市场共识。</p>
<p>Rowe Price 的 5.54% 分红收益率使其在分红贵族名单中名列前茅。事实上，在标准普尔 500 公司中，TROW 在连续增加分红至少 25 年的公司中，收益率排名第二，只有 <strong>Franklin Resources</strong> (NYSE:BEN) 的收益率更高，达到 6.76%。该公司除了分红外，还进行了回购，并且有充足的现金继续进行回购。市场的悲观情绪似乎在定价短期挑战，但长期前景并没有近期价格走势所暗示的那么严峻。</p>
<h2>West Pharmaceutical Services (WST)</h2>
<p><strong>West Pharmaceutical Services</strong> (NYSE:WST) 不幸地成为今年迄今表现最差的大型标准普尔 500 公司之一。由于第四季度财报对今年的指引疲软，股价年初至今下跌近 35%。</p>
<p>如果你在一月底之前是这里的股东，你可能并不太开心。但现在，预计的今年表现不佳的部分已经被定价，WST 可能变成了一个机会。</p>
<p>该公司在第四季度 2024 年的财报中超出了预期，调整后的每股收益为 1.82 美元，而市场共识为 1.72 美元，但投资者却关注于不尽如人意的指引。初步的 2025 年指引预计调整后的每股收益为 6 到 6.2 美元，远低于分析师预期的 7.44 美元。收入预测为 28.75 亿美元到 29.05 亿美元，也低于市场共识的 30.4 亿美元。</p>
<p>在 2025 年第一季度的财报发布会上，West Pharmaceutical 报告了超出预期的结果，净销售额为 6.98 亿美元， organic growth 为 2.1%，因此市场可能反应过度。管理层还提高了全年的指引，现在预计净销售额为 29.45 亿美元到 29.75 亿美元，调整后的每股收益为 6.15 到 6.35 美元。</p>
<p>我并不认为该股的分红收益率是其主要吸引力，但近年来其分红每年增加约 5% 到 6%。主要吸引力在于安全性和当前价格的上涨潜力。</p>
<p>市场共识目标价为 274.5 美元，意味着 30% 的上涨空间。即使是最低目标价 245 美元，也意味着分红贵族股票的良好上涨潜力。</p>
<h2>FactSet Research (FDS)</h2>
<p><strong>FactSet Research</strong> (NYSE:FDS) 的分红收益率大约为 1%，并不会让你太兴奋，但该公司仍然是分红贵族，并且本月将每股分红从 1.04 美元提高到 1.1 美元。如果你阅读与股市相关的新闻，你可能听说过这家公司，这就是它在华尔街的整合程度的一个例子。只要更广泛的金融服务行业增长，FactSet 也会随之增长。</p>
<p>它拥有稳定的客户基础，随着公司的成熟，回馈现金的比例也在增加。分红支付比率仅为 24%，因此未来还有更多的空间。2025 年第二季度收入同比增长 4.5%，达到 5.707 亿美元，organic subscription value 增长 4.1%，调整后的每股收益增长 1.4%。</p>
<p>我认为 FDS 是适合能够容忍较低收益率以换取稳定性和广泛经济护城河的分红增长投资者的核心持股。如果你想要快速收益，还有更好的选择，但如果你想要一只可以买入并忘记的股票，FactSet 正好符合这个要求。</p>
<p>这篇文章《5 月值得购买并永远持有的 3 只分红贵族股票》最初出现在 24/7 Wall St.。</p>

普信金融

西氏医药服务

<p>股市正在经历积极的趋势，因为关税担忧减轻，盈利报告超出预期，尤其是在科技行业。投资者被鼓励考虑股息贵族股票，这些股票不仅具有增长潜力，还提供不断上升的股息。普信金融（T Rowe Price，TROW）因其吸引人的估值和强劲的股息收益率而受到关注，而西氏医药服务（West Pharmaceutical Services，WST）尽管近期表现不佳，但被视为潜在机会。总体而言，增加股息贵族股票可能在经济不确定性中提供稳定性</p>

<ul>
<li>Instead of selling, you can buy these dividend stocks in May and go away.</li>
</ul>
<div class="lb-trans"><ul>
<li>与其出售，不如在五月购买这些分红股票，然后离开。</li>
</ul>
</div><ul>
<li>These Dividend Aristocrat stocks have both upside potential and pay dividends.</li>
</ul>
<div class="lb-trans"><ul>
<li>这些分红贵族股票既有上涨潜力，又支付分红。</li>
</ul>
</div><ul>
<li>These dividends are also likely to keep rising.</li>
</ul>
<div class="lb-trans"><ul>
<li>这些分红也很可能会继续上升。</li>
</ul>
</div><ul>
<li>Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; get started by clicking here.(Sponsor)</li>
</ul>
<div class="lb-trans"><ul>
<li>你在退休方面是领先还是落后？SmartAsset 的免费工具可以在几分钟内将你与财务顾问匹配，帮助你今天回答这个问题。每位顾问都经过严格筛选，必须以你的最佳利益为重。不要再浪费时间；点击这里开始吧。(赞助)</li>
</ul>
</div><p>The stock market has been on a winning streak as fears about tariffs start cooling. Earnings season has also been solid, and most tech companies have trounced estimates so far. As such, many investors have started to buy back in despite the long-term macro outlook still hanging in the balance.</p>
<div class="lb-trans"><p>随着对关税的担忧开始减弱，股市一直处于上涨状态。财报季也表现良好，大多数科技公司迄今为止都超出了预期。因此，尽管长期宏观前景仍不明朗，许多投资者已经开始重新买入。</p>
</div><p>It isn’t a bad idea to buy the dip on certain stocks since the administration has softened its stance on tariffs. China is reportedly considering engaging in tariff talks with the US, and the effective embargo is unlikely to last too long as inventories run out.</p>
<div class="lb-trans"><p>在某些股票上买入抄底并不是一个坏主意，因为政府已经软化了对关税的立场。中国 reportedly 正在考虑与美国进行关税谈判，随着库存的耗尽，有效的禁运不太可能持续太久。</p>
</div><p>Markets have mostly tumbled due to tariffs, so any news of tariffs being pulled back should lead to a recovery in the stock market. But even then, the negative GDP report in Q1 and the sudden shock with rapid changes in trade policy could lead to a downturn down the line. “Liberation Day” tariffs and the escalation with China began in April, so the true impact of these tariffs could be ahead. And a negative GDP report in Q2 implies a technical recession.</p>
<div class="lb-trans"><p>由于关税，市场大多下跌，因此任何关于关税被撤回的消息都应该会导致股市的复苏。但即便如此，第一季度的负 GDP 报告和贸易政策的快速变化带来的突然冲击可能会导致未来的下滑。“解放日” 关税和与中国的升级始于四月，因此这些关税的真正影响可能还在前方。而第二季度的负 GDP 报告意味着技术性衰退。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<p>With that in mind, it’s still a good idea to add some ballast to your portfolio in the form of Dividend Aristocrat stocks.</p>
<div class="lb-trans"><p>考虑到这一点，在你的投资组合中增加一些分红贵族股票作为防御性资产仍然是个好主意。</p>
</div><h2>T Rowe Price (TROW)</h2>
<div class="lb-trans"><h2>T Rowe Price (TROW)</h2>
</div><p><strong>Rowe Price</strong> (NASDAQ:TROW) is trading at historically cheap prices, and while it hasn’t been exactly stable in the past five years, it has now returned to prices that are hard to ignore. The stock surged in the second half of 2020 before languishing in the following years. It mostly traded in the $90 to $130 range since the latter half of 2022, and we’re currently at the lower end of this range.</p>
<div class="lb-trans"><p><strong>Rowe Price</strong> (NASDAQ:TROW) 的交易价格处于历史低位，尽管过去五年并不稳定，但现在已回到难以忽视的价格。该股在 2020 年下半年飙升，随后在接下来的几年中表现平平。自 2022 年下半年以来，它大多在 90 到 130 美元的区间内交易，目前处于该区间的下端。</p>
</div><p>Regardless, the technicals aren’t the only thing that’s good here. It is trading at a bargain valuation at just 10 times earnings. Historically, the median here has been around 15 times. The company also posted better-than-expected earnings in Q1 despite net outflows. The company reported net outflows of $8.6 billion in Q1 2025, mainly from U.S. equities, though this is less than half of the previous quarter’s outflow of $19.3 billion. But even then, Q1 EPS of $2.23 came in above the $2.12 consensus.</p>
<div class="lb-trans"><p>尽管如此，技术面并不是这里唯一的亮点。它的市盈率仅为 10 倍，估值相对便宜。历史上，这里的中位数大约为 15 倍。尽管净流出，但该公司在第一季度发布了超出预期的财报。该公司报告 2025 年第一季度净流出 86 亿美元，主要来自美国股票，尽管这仅为上一季度 193 亿美元流出的不到一半。但即便如此，第一季度每股收益为 2.23 美元，超过了 2.12 美元的市场共识。</p>
</div><p>Rowe Price’s 5.54% dividend yield places it near the top of the dividend aristocrat list. In fact, among S&amp;P 500 companies that have increased dividends for at least 25 consecutive years, TROW ranks second highest in yield, and only <strong>Franklin Resources</strong> (NYSE:BEN) has a higher yield at 6.76%. This company has also been doing buybacks in addition to its dividends and has plenty of cash to keep doing so. The market’s pessimism seems to be pricing in short-term challenges, but the long-term picture is less dire than the recent price action suggests.</p>
<div class="lb-trans"><p>Rowe Price 的 5.54% 分红收益率使其在分红贵族名单中名列前茅。事实上，在标准普尔 500 公司中，TROW 在连续增加分红至少 25 年的公司中，收益率排名第二，只有 <strong>Franklin Resources</strong> (NYSE:BEN) 的收益率更高，达到 6.76%。该公司除了分红外，还进行了回购，并且有充足的现金继续进行回购。市场的悲观情绪似乎在定价短期挑战，但长期前景并没有近期价格走势所暗示的那么严峻。</p>
</div><h2>West Pharmaceutical Services (WST)</h2>
<div class="lb-trans"><h2>West Pharmaceutical Services (WST)</h2>
</div><p><strong>West Pharmaceutical Services</strong> (NYSE:WST) has earned the unfortunate distinction of being among the worst-performing big S&amp;P 500 companies so far this year. Shares are down nearly 35% year-to-date after a Q4 earnings report that had weak guidance for the year.</p>
<div class="lb-trans"><p><strong>West Pharmaceutical Services</strong> (NYSE:WST) 不幸地成为今年迄今表现最差的大型标准普尔 500 公司之一。由于第四季度财报对今年的指引疲软，股价年初至今下跌近 35%。</p>
</div><p>If you’ve been a shareholder here before late January, you’re probably not the happiest. But now that much of the expected underperformance for this year has been priced in, WST may have turned into an opportunity.</p>
<div class="lb-trans"><p>如果你在一月底之前是这里的股东，你可能并不太开心。但现在，预计的今年表现不佳的部分已经被定价，WST 可能变成了一个机会。</p>
</div><p>The company beat Q4 2024 earnings expectations with adjusted EPS of $1.82 versus $1.72 consensus, but investors have fixated on the underwhelming guidance. The initial 2025 guidance projected adjusted EPS of $6 to $6.2, which is well below analyst expectations of $7.44. The revenue forecast of $2.875 billion to $2.905 billion also came in lower than the consensus of $3.04 billion.</p>
<div class="lb-trans"><p>该公司在第四季度 2024 年的财报中超出了预期，调整后的每股收益为 1.82 美元，而市场共识为 1.72 美元，但投资者却关注于不尽如人意的指引。初步的 2025 年指引预计调整后的每股收益为 6 到 6.2 美元，远低于分析师预期的 7.44 美元。收入预测为 28.75 亿美元到 29.05 亿美元，也低于市场共识的 30.4 亿美元。</p>
</div><p>In its Q1 2025 earnings release on April 24, West Pharmaceutical reported better-than-expected results with net sales of $698 million and organic growth of 2.1%, so the market may have overreacted. Management also increased its full-year guidance and now sees net sales of $2.945 billion to $2.975 billion and adjusted EPS of $6.15-$6.35.</p>
<div class="lb-trans"><p>在 2025 年第一季度的财报发布会上，West Pharmaceutical 报告了超出预期的结果，净销售额为 6.98 亿美元， organic growth 为 2.1%，因此市场可能反应过度。管理层还提高了全年的指引，现在预计净销售额为 29.45 亿美元到 29.75 亿美元，调整后的每股收益为 6.15 到 6.35 美元。</p>
</div><p>I don’t see the stock’s dividend yield as its main appeal, but it has increased its dividend at approximately 5% to 6% annually in recent years. The main draw is the safety and upside potential from current prices.</p>
<div class="lb-trans"><p>我并不认为该股的分红收益率是其主要吸引力，但近年来其分红每年增加约 5% 到 6%。主要吸引力在于安全性和当前价格的上涨潜力。</p>
</div><p>The consensus price target of $274.5 implies 30% upside. Even the lowest price target of $245 implies solid upside potential for a dividend aristocrat stock.</p>
<div class="lb-trans"><p>市场共识目标价为 274.5 美元，意味着 30% 的上涨空间。即使是最低目标价 245 美元，也意味着分红贵族股票的良好上涨潜力。</p>
</div><h2>FactSet Research (FDS)</h2>
<div class="lb-trans"><h2>FactSet Research (FDS)</h2>
</div><p><strong>FactSet Research</strong> (NYSE:FDS) won’t excite you much either with its dividend yield, as it sits at around 1%, but the company is still a Dividend Aristocrat and has raised its dividend from $1.04 to $1.1 per share just this month. This is likely a company you’ve heard of a few times if you read stock market-related news, and that’s one example of how integrated it is into Wall Street. As long as the broader financial services sector grows, so will FactSet.</p>
<div class="lb-trans"><p><strong>FactSet Research</strong> (NYSE:FDS) 的分红收益率大约为 1%，并不会让你太兴奋，但该公司仍然是分红贵族，并且本月将每股分红从 1.04 美元提高到 1.1 美元。如果你阅读与股市相关的新闻，你可能听说过这家公司，这就是它在华尔街的整合程度的一个例子。只要更广泛的金融服务行业增长，FactSet 也会随之增长。</p>
</div><p>It has a sticky client base, and the company is returning more cash as it matures. The dividend payout ratio is only 24%, so there’s room for more down the line. Q2 2025 revenue rose 4.5% year-over-year to $570.7 million, with organic subscription value up 4.1% and adjusted EPS up 1.4%.</p>
<div class="lb-trans"><p>它拥有稳定的客户基础，随着公司的成熟，回馈现金的比例也在增加。分红支付比率仅为 24%，因此未来还有更多的空间。2025 年第二季度收入同比增长 4.5%，达到 5.707 亿美元，organic subscription value 增长 4.1%，调整后的每股收益增长 1.4%。</p>
</div><p>I see FDS as a core holding for dividend growth investors who can tolerate a lower yield in exchange for solid consistency and a wide economic moat. There are better options if you want fast gains, but if you want a stock you can buy and forget, FactSet fits the bill.</p>
<div class="lb-trans"><p>我认为 FDS 是适合能够容忍较低收益率以换取稳定性和广泛经济护城河的分红增长投资者的核心持股。如果你想要快速收益，还有更好的选择，但如果你想要一只可以买入并忘记的股票，FactSet 正好符合这个要求。</p>
</div><p>The post 3 Dividend Aristocrat Stocks To Buy in May and Hold Forever appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>这篇文章《5 月值得购买并永远持有的 3 只分红贵族股票》最初出现在 24/7 Wall St.。</p>
</div>

5 月份值得买入并长期持有的 3 只股息贵族股票